Diaceutics Announces Collaboration with Snowflake to Accelerate Precision Medicine with Scalable Real-World Data Solutions
Belfast, Ireland – 30 October 2025 — Diaceutics, a global leader in precision medicine and diagnostic-guided therapy commercialization, today announced a collaboration with Snowflake, the AI Data Cloud company, to deliver scalable solutions that unite diagnostic and clinical real-world data (RWD). Through the collaboration, Diaceutics assets will be available via Snowflake Data Sharing, empowering biopharma, diagnostics, and clinical stakeholders to accelerate the adoption of biomarker-driven therapies and improve patient outcomes.
By combining Diaceutics’ proprietary diagnostic and laboratory datasets with Snowflake’s secure and scalable AI Data Cloud for Healthcare & Life Sciences, life science organizations can streamline how they ingest, harmonize and activate data across research, development and commercialization.
Key benefits of the collaboration include:
Unified Data Access: Eliminate silos by linking diagnostic, lab, claims and clinical data in one governed environment.
Governance & Flexibility: Balance performance, cost and compliance controls with compute options inside Snowflake or through Diaceutics analytics layers.
Faster Insights: Accelerate patient stratification, biomarker feasibility, site selection and market access analytics.
Seamless Activation: Enable downstream use across business intelligence, AI/M, and operational platforms without complex data transfers.
“Precision medicine relies on the seamless integration of diagnostic and clinical insights. By more closely integrating Diaceutics’ unmatched diagnostic data with Snowflake’s easy, connected and trusted platform, we are enabling life science organizations to identify patients earlier, optimize clinical development, and accelerate commercialization strategies,” said Jordan Clark, Chief Data Officer, Diaceutics.
“The real-world data challenges facing pharma have always been speed, scale, and actionability. This collaboration will allow us to more effectively deliver diagnostic-driven evidence faster easily link that evidence with other data sources, and make it useful for commercial and clinical decision-making more quickly ,” said Scott Phillips, Vice President, Real-World Data, Diaceutics.
The collaboration is already helping life science teams:
Conduct biomarker feasibility assessments more efficiently by linking diagnostic and molecular test results directly to clinical outcomes.
Deliver brand alert signals, providing commercial teams with timely triggers when diagnostic activity indicates shifts in physician behavior or patient eligibility.
Improve payer and reimbursement modeling through predictive simulations of diagnostic usage patterns.
Access Diaceutics listings on Snowflake Marketplace here. In select regions, Diaceutics is eligible for Snowflake’s Marketplace Capacity Drawdown (MCD)*. With the Snowflake MCD program, a portion of committed capacity can be used for Snowflake Marketplace purchases.
About Diaceutics
Diaceutics is the leading precision medicine services company that integrates diagnostic strategy, real-world data, laboratory operations, and market commercialization to accelerate the adoption of biomarker-driven therapies. With a global network of laboratories, a rich diagnostic dataset, and proprietary analytics, Diaceutics helps life science, diagnostic, and clinical partners close the gap between innovation and real-world implementation. Learn more at www.diaceutics.com.
Media Contacts
Diaceutics
[email protected]
*Only available in select regions. See documentation for full program details.
